KAHR Announces First Patient Dosed in DSP107 Treatment of Solid Tumors Phase 1/2 Clinical Trial
Jerusalem based KAHR MEDICAL, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, started treating the first patient in its Phase 1/2 clinical trial (NCT04440735) assessing its lead product, DSP107,…
Continue Reading
KAHR Announces First Patient Dosed in DSP107 Treatment of Solid Tumors Phase 1/2 Clinical Trial